Mobocertinib succinate, the succinate salt of Mobocertinib (TAK788; AP32788; Exkivity), is an approved medication for the treatment of non-small cell lung cancer (NSCLC). It acts as an irreversible inhibitor of EGFR and HER2 oncogenic mutants (e.g. exon 20 insertions), and shows high selectivity over WT EGFR. As of 9/15/2021, mobocertinib has been approved by FDA via the acceleration channel for treating metastatic NSCLC with EGFR exon 20 insertion mutations.

纯度：≥98%

CAS：2389149-74-8